Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: is it justified?
Sumethkul
V
V
Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand. ravsm@mahidol.ac.th
Ingsathit
A
A
Leelasa-Nguan
P
P
Jirasiritham
S
S
D000328:Adult; D005500:Follow-Up Studies; D006085:Graft Survival; D006509:Hepatitis B / Q000150:complications / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000150:complications / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors
D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid